好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Data-driven deep phenotyping of multiple sclerosis patients using patient-reported outcome measures
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
3-015

To identify distinct clusters of persons with multiple sclerosis (PwMS) with shared impairment patterns across 11 functional domains.

PwMS experience wide-ranging symptoms across multiple domains, alone or in combination, with varied severity. We sought to characterize naturally occurring clusters of MS using seemingly heterogeneous longitudinal patient-reported outcome measure (PROMs) responses, which are increasingly used in clinical trials and practice.

From the electronic health records of 6,619 MS patients with extended care (≥2 encounters 6 months apart) at a tertiary referral center between 2008-2015, we abstracted responses for 11 validated MS-PROMs include 8 MS Performance Scales© (mobility, hand function, vision, fatigue, cognition, bladder/bowel, sensory, spasticity) and 3 MS Functional Scales (pain, depression, tremor/coordination). We applied unsupervised machine learning through mixture modeling (latent profile analysis) to the 11 MS-PROMs at baseline, to identify a set of discrete and non-overlapping clusters of MS patients with similar impairment patterns.

Nine patient clusters were detected, and were differentiated by low (4 clusters), medium (1 cluster), and high (4 clusters) levels of mobility impairment. The low mobility impairment clusters were differentiated by low impairment across domains (31.7%), to moderate fatigue (18.7%), to moderate fatigue + moderately-high sensory dysfunction (7.9%), and to moderately-high fatigue + pain (10%). The medium mobility cluster had moderately-high impairment across domains (10.2%). The clusters with high mobility impairments varied with mild impairment (8.3%) to high impairment (4.1%) across all domains, and two clusters with moderate impairment across domains but not sensory dysfunction (low [3.9%] vs high [5.1%]). 

            The clusters also varied by sociodemographic and clinical attributes. The most impaired cluster had the highest proportion of Black patients, the lowest quality of life, and lived in ZIP codes with the highest levels of deprivation. 

We leveraged PROMs to innovatively deep phenotype MS patients into distinct subgroups with varying levels of disability and symptomatology.

Authors/Disclosures
Farren Briggs, PhD (University of Miami Miller School of Medicine)
PRESENTER
The institution of Prof. Briggs has received research support from NIH.
Doug Gunzler No disclosure on file
Daniel Ontaneda, MD, PhD, FAAN (Cleveland Clinic) Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.
Deborah M. Miller, PhD (Cleveland Clinic Foundation) Dr. Miller has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file